SVIN Mission Thrombectomy’s Post

We're excited to announce the publication of our digital quantitative study on the Myasthenia Gravis Core Examination for telemedicine evaluations in Frontiers in Neurology! (link: https://lnkd.in/gqnTpiRU) Myasthenia gravis impairs the communication between nerves and muscles, leading to debilitating muscle weakness and fatigue. Myasthenia Gravis (MG) is often considered a good prototype of an autoimmune disease. This first round of validation for the Care Constitution Corp.'s digital health AI-powered software (link: https://lnkd.in/gAiB8K4w) was made possible thanks to the collaborative efforts of the MGnet network (NIH U54 NS115054). This network brings together renowned neurologists from George Washington University, Harvard Medical Center, Duke University, Yale University, University of Chicago, and the University of Alabama at Birmingham.

Innovation drives the NHS, and Muslim healthcare professionals play a vital role in advancing research and medical breakthroughs. Many Muslim doctors and researchers contribute to groundbreaking studies in fields such as cardiology, neurology, and cancer research. Their expertise and dedication help push the boundaries of medicine, leading to better treatments and improved outcomes for patients. Today, we celebrate their contributions to science, health, and the future of medicine. Hashtags: #MedicalInnovation #NHSResearch #MuslimDoctorsassciation

New insights from the RESCUE-ICAS registry, presented at #SVIN2024 by Dr. Sami Al Kasab, reveal that rescue stenting after mechanical thrombectomy in patients with large vessel occlusion (LVO) stroke due to intracranial atherosclerotic stenosis (ICAS) improves reperfusion and 90-day functional independence rates, but also increases procedural complications. This study sheds light on the challenges of treating ICAS-LVO, a condition affecting 10-30% of LVO stroke patients, and highlights the need for tailored approaches in neurointervention. Read the full article below: https://lnkd.in/e3kzt9du #StrokeResearch #Neurointervention #SVIN2024 #muschealth #ChangingWhatsPossible MUSC Health MUSC Children's Health Medical University of South Carolina MUSC College of Medicine MUSC College of Health Professions MUSC College of Graduate Studies Sami Al Kasab Society of Vascular and Interventional Neurology (SVIN)

Understanding Dural Arteriovenous Fistula with Dr. Adi Iyer MD Dural arteriovenous fistula (DAVF) is a rare vascular condition where abnormal connections (fistulas) form between branches of arteries and veins in the dura mater, the brain's covering. The dural arteries deliver high-pressure, oxygen-rich blood to the brain, while the dural veins return deoxygenated, low-pressure blood to the heart. DAVF causes high-pressure arterial blood to flow into veins or sinuses meant for low-pressure blood, which can lead to ruptures, brain hemorrhages, and other neurological issues. Meet Dr. Adit Iyer, a board-certified, fellowship-trained neurosurgeon specializing in vascular diseases of the brain and spine at Pacific Neuroscience Institute (PNI). As one of California’s few dual-trained neurosurgeons, Dr. Iyer offers both minimally invasive open surgical techniques and incisionless catheter-based procedures to treat strokes, aneurysms, AVMs, tumors, and pain. Discover expert care and advanced treatment options with Dr. Iyer, dedicated to ensuring the best outcomes for your vascular health. #DAVF #NeurovascularHealth #ExpertCare #HealthcareExcellence #BrainHealth

What you need to know about implementing #Alzheimers #diagnostics in clinical practice. Register here 👇 #healthsystempreparedness #implementationscience #earlydetection #accuratediagnosis #DAC Davos Alzheimer's Collaborative

The research keeps coming. CND Life Sciences announces that a retrospective chart review of 97 patients published in the December 18, 2024, issue of Frontiers in Neurology shows that the results of the Syn-One Test effected a change in the clinical care of 78% of the patients. The publication demonstrated the clinical utility of skin biopsy testing in the diagnosis and evaluation of synucleinopathies. These diseases, which include #ParkinsonsDisease, #dementiawithLewybodies, and #multiplesystematrophy, are often difficult to diagnose accurately leading to delays or errors in medical management.    “For too long, neurologists have needed a simple, accurate test to help diagnose Parkinson’s disease, dementia with Lewy bodies, and other related disorders,” said Todd Levine, MD, Chief Medical Officer of CND Life Sciences. “This study shows that by examining nerves in the skin, the Syn-One Test® fulfills that need and contributes to clinical practice and decision-making.    See the full news release https://lnkd.in/gcwJArzn   #DementiawithLewybodies #ParkinsonsResearch #Parkinsons #CNDLifeSciences #FrontiersInNeurology Rick Morello Padma R. Mahant, MD

👉Southeast Neuroscience Center LLC (SNC) has treated the neurological needs of Southeast Louisiana patients since its founding in 1996. 🩺SNC’s team members treat the full spectrum of neurological disorders. Diagnostic testing including EMG, routine and ambulatory EEG, as well as more advanced electrophysiologic testing (VEP, SSEP, BAER are a critical part of the diagnosis and management of often cryptogenic medical conditions. 🩺SNC’s in-house imaging facility offers cutting edge high-field closed and now fully open MRI systems with high weight limits as well as a newly added high-definition 128-channel CT scanner with very low radiation dosing technology. Because these imaging modalities are not hospital-owned, costs to patients are often significantly less than at other such facilities. SNC is accepting new patients that are self-referred and provider-referred. All insurances are accepted. SNC makes a special commitment to those without insurance by tailoring affordable payments plans when necessary. #SoutheastNeuroscienceCenter #NeuroCareSpecialists #BrainHealthExperts #NeuroScienceClinic #NeuroCareSolutions

Earlier today, Paola Zaratin (SSC Co-chair PROMS) had the privilege of moderating a distinguished panel discussion during the Platinum Session at the #BrainInnovationDays2024. She was joined by eminent experts in neurology, including Astri Arnesen (President of European Federation of Neurological Associations) Pavel Balabanov from the European Medicines Agency, Dimitrios Georgiopoulos from Merck, and Gianni FRANCO from the from the Belgian francophone Parkinson’s Association. During her introduction, Paola Zaratin established the context by elucidating the complementary role of Patient Experience Data (PED) in enhancing current clinical outcomes, encompassing clinical trials and broader assessments to 𝐮𝐧𝐦𝐚𝐬𝐤 𝐭𝐡𝐞 𝐡𝐢𝐝𝐝𝐞𝐧 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐢𝐜𝐞𝐛𝐞𝐫𝐠. She outlined three key themes for discussion: Opportunities and Challenges, Best Practices, and Implementation. This structured approach facilitated a focused examination of how PED can be effectively integrated into neurology 𝐭𝐨 𝐞𝐧𝐚𝐛𝐥𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐰𝐢𝐭𝐡 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐢𝐧𝐩𝐮𝐭 𝐚𝐧𝐝 𝐭𝐡𝐮𝐬 𝐢𝐦𝐩𝐫𝐨𝐯𝐞 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬. Key questions posed by the panelists included the significance of collecting PED to ensure inclusive patient representation, the diverse perspectives on opportunities and challenges from clinical and industry viewpoints, and the evolution of PED within regulatory and health technology assessment processes. The panel underscored the paramount importance of collaboration among patients, healthcare professionals, industry stakeholders, regulators, and policymakers to enhance the credibility and utilization of PED. 𝐓𝐡𝐚𝐧𝐤𝐬 𝐭𝐨 European Brain Council 𝐟𝐨𝐫 𝐠𝐢𝐯𝐢𝐧𝐠 𝐮𝐬 𝐭𝐡𝐞 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐭𝐨 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐜𝐫𝐨𝐬𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐭𝐨 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐭𝐡𝐞 𝐮𝐩𝐭𝐚𝐤𝐞 𝐨𝐟 𝐝𝐢𝐯𝐞𝐫𝐬𝐞 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞 𝐝𝐚𝐭𝐚, 𝐟𝐫𝐨𝐦 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐭𝐨 𝐜𝐚𝐫𝐞. 𝐉𝐨𝐢𝐧 𝐮𝐬 𝐭𝐨 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬 𝐭𝐡𝐞 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐚𝐭 𝐭𝐡𝐞 𝐏𝐥𝐞𝐧𝐚𝐫𝐲 𝐏𝐑𝐎𝐌𝐒 𝐞𝐯𝐞𝐧𝐭 𝐢𝐧 𝐁𝐚𝐯𝐞𝐧𝐨, 𝐞𝐧𝐭𝐢𝐭𝐥𝐞𝐝 ‘𝐃𝐢𝐠𝐢𝐭𝐚𝐥 “𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐨𝐟 𝐏𝐰𝐌𝐒 𝐢𝐧𝐩𝐮𝐭” 𝐢𝐧 𝐭𝐡𝐞 𝐞𝐫𝐚 𝐨𝐟 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞’.   On our website, you will find detailed information on ➡ how to participate online: https://lnkd.in/dAEVXfVg ➡ download the complete agenda of speakers: https://lnkd.in/dmMQCWVh   #BIDays #PROMS #Neurology #PatientExperience #BrainInnovationDays2024

"Although the acute urgency of the COVID-19 pandemic has been in the world’s rearview mirror for some time, the virus continues to affect a portion people who contracted it, even two years after their initial recovery. A new paper published in The Lancet Regional Health Western Pacific details a handful of brain abnormalities identified on the MRI scans of people who had moderate to severe cases of COVID. The imaging findings align with the patients’ lingering cognitive complaints and fatigue issues, indicating that, for some, the virus’ impact could persist for years." Continue reading "Even two years after recovery, damage to multiple regions of the brain persists in COVID patients" #COVID19 #damage #brains #abnormalities #yourhealthmatters #radiologist #imaging #openmri #pictures #callus #vistsus #shoplocal #buylocal #UprightMRIOfDeerfield

We are very pleased to share positive initial data from our Phase 1/2 FORTITUDE™ trial for people living with facioscapulohumeral muscular dystrophy (#FSHD). We are now focused on accelerating our registrational plans as we understand the urgency for a treatment option for the FSHD community. FSHD is a rare and variable hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. These data represent another important milestone in our efforts to advance meaningful therapies for people living with rare neuromuscular diseases, including FSHD, and further reinforce the promise of our AOC platform to profoundly improve people’s lives. Today at 8:00am ET, Avidity’s management team will be joined by Jeffrey M. Statland, MD, Professor of Neurology, University of Kansas Medical Center, in an investor & analyst event highlighting the initial data from the FORTITUDE trial. Visit our website to register for the event here: https://lnkd.in/eCbZefbR. For more information on our data from FORTITUDE, read our press release: https://lnkd.in/e6ET3uYs